Cytosorbents’ (CTSO) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research note published on Thursday,Benzinga reports. They currently have a $10.00 price target on the medical research company’s stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.38.

Cytosorbents Stock Down 10.6%

Shares of CTSO stock opened at $0.60 on Thursday. Cytosorbents has a 52-week low of $0.50 and a 52-week high of $1.39. The stock has a market cap of $37.69 million, a price-to-earnings ratio of -4.62 and a beta of 1.36. The firm’s 50-day moving average is $0.69 and its 200-day moving average is $0.75. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.71 and a current ratio of 2.11.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Wednesday, March 25th. The medical research company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). The business had revenue of $9.23 million for the quarter, compared to the consensus estimate of $9.22 million. Cytosorbents had a negative return on equity of 131.86% and a negative net margin of 22.12%. Sell-side analysts predict that Cytosorbents will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its stake in shares of Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares during the period. Citadel Advisors LLC increased its stake in Cytosorbents by 127.3% during the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after acquiring an additional 36,790 shares during the period. GSA Capital Partners LLP acquired a new position in Cytosorbents in the 3rd quarter valued at $105,000. CIBC Bancorp USA Inc. acquired a new position in Cytosorbents in the 3rd quarter valued at $161,000. Finally, CM Management LLC lifted its position in shares of Cytosorbents by 3.1% during the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after acquiring an additional 38,128 shares during the period. 32.87% of the stock is currently owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.